Arbutus Biopharma (ABUS) Other Gross PP&E Adjustments (2016 - 2024)
Historic Other Gross PP&E Adjustments for Arbutus Biopharma (ABUS) over the last 16 years, with Q4 2024 value amounting to $15.3 million.
- Arbutus Biopharma's Other Gross PP&E Adjustments rose 65.31% to $15.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year increase of 65.31%. This contributed to the annual value of $15.3 million for FY2024, which is 65.31% up from last year.
- Arbutus Biopharma's Other Gross PP&E Adjustments amounted to $15.3 million in Q4 2024, which was up 65.31% from -$1.1 million recorded in Q3 2024.
- Arbutus Biopharma's Other Gross PP&E Adjustments' 5-year high stood at $15.3 million during Q4 2024, with a 5-year trough of -$2.7 million in Q1 2020.
- Over the past 5 years, Arbutus Biopharma's median Other Gross PP&E Adjustments value was -$1.6 million (recorded in 2023), while the average stood at $2.1 million.
- Data for Arbutus Biopharma's Other Gross PP&E Adjustments shows a peak YoY increase of 2383.49% (in 2024) and a maximum YoY decrease of 65.31% (in 2024) over the last 5 years.
- Arbutus Biopharma's Other Gross PP&E Adjustments (Quarter) stood at $12.1 million in 2020, then rose by 9.24% to $13.3 million in 2021, then rose by 6.5% to $14.1 million in 2022, then increased by 7.3% to $15.2 million in 2023, then grew by 0.65% to $15.3 million in 2024.
- Its last three reported values are $15.3 million in Q4 2024, -$1.1 million for Q3 2024, and -$1.2 million during Q2 2024.